Skip to main content

Table 1 Patient characteristics at baseline and virological treatment failure at month 6 and 12

From: A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort

Characteristics All patients n = 874 GRTa NFLGb (n = 16)
Month 6 (n = 47) Month 12 (n = 30)
Gender: female/male 527/347 (60/40%) 23/24 (49/51%) 17/13 (57/43%) 5/11 (31/69%)
Age: years (median, IQR) 33 (11) 30 (13) 30 (9) 31 (13)
WHO clinical stage
 stage I 149 (17.0%) 4 (8.5%) 3 (10.0%) 1 (6.3%)
 stage II 223 (25.5%) 13 (27.7%) 8 (26.7%) 5 (31.3%)
 stage III 372 (42.6%) 19 (40.4%) 12 (40.0%) 6 (37.5%)
 stage IV 130 (14.9%) 11 (23.4%) 7 (23.3%) 4 (25.0%)
NRTI
 Tenofovir 467 (53.4%) 28 (59.6%) 16 (53.3%) 12 (75.0%)
 Zidovudine 362 (41.4%) 15 (31.9%) 10 (33.3%) 4 (25.0%)
 Stavudine 44 (5.0%) 4 (8.5%) 4 (13.3%) 0 (0.0%)
NNRTI
 Nevirapine 380 (43.5%) 24 (51.1%) 16 (53.3%) 10 (62.5%)
 Efavirenz 494 (56.5%) 23 (48.9%) 14 (46.7%) 6 (37.5%)
Laboratory values
 CD4+ T-cells/μl: mean; SD 143; 87 108; 80 113; 87 86; 76
 HIV RNA log10 copies/ml: mean; SD 5.2; 0.8 5.4; 0.9 5.2; 1 5.8; 0.8
  1. Number of patients with viral failure whose virus was sequenced with agenotypic resistance testing (GRT) or bnear-full length sequencing (NFLG) at baseline, month 6 and/or 12; NRTI: nucleoside analogue reverse transcriptase inhibitors; NNRTI: non-nucleoside-analogue reverse transcriptase inhibitors. GRT was successful in 47 out of 51 tested patients and 30 out of 33 tested patients at month 6 and month 12, respectively